Loading…
Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.
Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.
Sells its machines to clinics largely through distributors, and earns repeat income from the single-use cartridges each treatment uses up, so a machine already installed keeps generating orders. Exports are a large part of sales.
Moat: narrow (IP / patents, regulatory licence). Patented energy-based device technology plus regulatory clearances across many export markets.
Headquarters: Seoul, South Korea · Founded: 2007 · Employees: 528
Size CLASSYS (214150.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $1.25B, the 203rd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩25,850 on 6 Nov 2026.
Performance Over six months the shares fell 53.5%, against -5.5% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 25.5% over the last twelve months (peer median +14.2%); the operating margin is 46.0% (peer median 6.3%).
Valuation It trades at 12.1× forward earnings against a peer median of 30.3× (cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -43 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.0 points above its cost of capital (5.8% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩369B | ₩337B | ₩243B | ₩180B | ₩142B |
| Revenue growth | — | +39% | +35% | +27% | — |
| Gross profit | ₩266B | ₩250B | ₩187B | ₩139B | ₩107B |
| EBITDA | ₩185B | ₩185B | ₩130B | ₩93.9B | ₩72.3B |
| Net income | ₩138B | ₩132B | ₩97.9B | ₩74.2B | ₩75.4B |
| Free cash flow | ₩68.1B | ₩101B | ₩98.7B | ₩60.2B | ₩27.3B |
| Capital expenditure | ₩15.8B | ₩19.3B | ₩10.8B | ₩6.11B | ₩28.0B |
| Total debt | ₩148B | ₩86.8B | ₩91.1B | ₩65.6B | ₩67.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CLASSYS 214150.KS | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% |
| Hugel 145020.KS | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% |
| Lunit 328130.KS | $846M | -25% | +24% | -76% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214150.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.8% | +1.2% | 5th lowest of 21 |
| 6-month return | -53.5% | -5.5% | lowest of 20 |
| Distance from 52-week high | -66.7% | -33.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +25.5% | +14.2% | 3rd highest of 19 |
| Operating margin | 46.0% | 6.3% | highest of 19 |
| Forward P/E | 12.1× | 30.3× | cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -8.7% | 10.4% | least demanding of 9 |
| Growth delivered (Del g) | +34.5% | +10.1% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | -43.2 pp | -3.1 pp | least demanding of 9 |
| ROIC minus cost of capital | +16.0 pp | -2.5 pp | 4th highest of 20 |
| EV / EBITDA | 9.2× | 22.4× | 2nd cheapest of 5 |
| Net debt / EBITDA | 0.1× | -2.1× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |